Renaissance Technologies
ACHL

Renaissance Technologies’s Achilles Therapeutics ACHL Stock Holding History

Renaissance Technologies’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-547,233
Closed -$624K – 3950
2024
Q4 		$624K Sell
547,233
-90,900
-14% -$93.7K ﹤0.01% 2749
2024
Q3 		$651K Sell
638,133
-44,601
-7% -$35.7K ﹤0.01% 2662
2024
Q2 		$556K Sell
682,734
-323,025
-32% -$284K ﹤0.01% 2651
2024
Q1 		$1.26M Buy
1,005,759
+506,764
+102% +$547K ﹤0.01% 2335
2023
Q4 		$444K Buy
498,995
+61,467
+14% +$52.7K ﹤0.01% 2836
2023
Q3 		$398K Sell
437,528
-12,205
-3% -$11.6K ﹤0.01% 2818
2023
Q2 		$425K Buy
449,733
+69,500
+18% +$66K ﹤0.01% 2964
2023
Q1 		$364K Sell
380,233
-104,500
-22% -$113K ﹤0.01% 3033
2022
Q4 		$436K Buy
484,733
+403,700
+498% +$680K ﹤0.01% 3025
2022
Q3 		$183K Sell
81,033
-6,200
-7% -$17.5K ﹤0.01% 3413
2022
Q2 		$220K Buy
87,233
+56,700
+186% +$140K ﹤0.01% 3612
2022
Q1 		$90K Buy
30,533
+5,000
+20% +$17.8K ﹤0.01% 3814
2021
Q4 		$128K Buy
+25,533
New +$155K ﹤0.01% 3637

Other funds holding ACHL

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Renaissance Technologies's ACHL Position: Q1 2025 in Review

Renaissance Technologies sold out of Achilles Therapeutics (ACHL) in Q1 2025, closing a stake of 547,233 shares — an estimated $624K sold.

Renaissance Technologies first reported a position in ACHL in Q4 2021 and held it in 13 quarters. The position peaked at $1.26M in Q1 2024. 6 funds tracked by Wall St. Rank hold ACHL as of Q1 2025.

  • Renaissance Technologies reported no remaining Achilles Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Renaissance Technologies sold 547,233 Achilles Therapeutics shares in Q1 2025, an estimated $624K.
  • Renaissance Technologies first reported a position in Achilles Therapeutics in Q4 2021 and held it in 13 quarters.
  • Renaissance Technologies's Achilles Therapeutics position peaked at $1.26M in Q1 2024.
  • 6 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2025.

Based on Renaissance Technologies's 13F filing for Q1 2025, filed 14 May 2025.